Skip to content
drillr.ai
Sign up

AZN.CA

AstraZeneca PLC

Healthcare · Drug Manufacturers - General · GB

Also listed · AZN →AZNVD →AZNVF →MILE.CA →OJO.CA →
—
Ask drillr

  • Oct 6, 2026, 18:30 UTC

    Multiply Labs completed a new funding round led by ASTRAZENECA PLC, LINGOTTO INVESTMENT MANAGEMENT LLP, TERADYNE, INC, and Strange Ventures.

    Source:

  • Oct 6, 2026, 12:15 UTC

    Multiply Labs raised $75 million in Series B funding led by Dr. Patrick Soon-Shiong and NantWorks, bringing its total funding to more than $100 million.

    Source:

  • Oct 2, 2026, 06:58 UTC

    AstraZeneca and Daiichi Sankyo entered into a clinical collaboration with Summit Therapeutics to test Datroway in combination with ivonescimab across multiple tumour types, including lung and breast cancers.

    Source:

  • Oct 2, 2026, 06:30 UTC

    Daiichi Sankyo and AstraZeneca agreed to collaborate on clinical trials.

    Source:

  • Sep 29, 2026, 11:25 UTC

    Aquestive Therapeutics, Inc. appointed Richard J. Daly as a director effective October 14, 2026, granting him 57,000 stock options under the company's 2018 Equity Incentive Plan.

  • Sep 29, 2026, 04:01 UTC

    Akeso shares surged as much as 15.65% to HK$106.4 in morning trading after its overseas partner Summit Therapeutics received a US$2 billion strategic investment from AstraZeneca.

    Source:

  • Sep 29, 2026, 02:09 UTC

    AstraZeneca and Summit Therapeutics announced they will jointly run a series of clinical trials combining ivonescimab with AstraZeneca's cancer therapies, and signed a preliminary agreement to explore ivonescimab combinations with several AstraZeneca antibody-drug conjugates.

    Source:

  • Sep 28, 2026, 21:48 UTC

    AstraZeneca agreed to invest $2 billion in newly issued preferred equity of Summit Therapeutics, convertible into common stock at a 1:1,000 ratio, representing a common stock price of $18.36 per share.

    Source:

  • Sep 28, 2026, 21:21 UTC

    Eccogene received a $50 million milestone payment from AstraZeneca after initiating a global Phase 3 program for the drug elecoglipron (AZD5004/ECC5004).

    Source:

  • Sep 28, 2026, 15:05 UTC

    AstraZeneca's oncology sales rose 15% in H1 2026, supported by newer drugs, label expansions and a deep pipeline.

    Source:

  • Sep 27, 2026, 10:55 UTC

    The European Commission issued an implementing decision on September 25, 2026 formally revoking the EU marketing authorization for Hansoh Pharmaceutical's innovative drug Aumseqa (aumolertinib) as monotherapy.

    Source:

  • Sep 24, 2026, 15:58 UTC

    IRLAB Therapeutics AB appointed Jan-Fredrik "Janne" Backman as Chairman of the Board, succeeding Carola Lemne, who stepped down in September 2026.

    Source:

  • Sep 24, 2026, 06:07 UTC

    EcoCeres announced a partnership with AstraZeneca to supply hydrotreated vegetable oil (HVO) renewable fuel for backup power generation at AstraZeneca's pharmaceutical manufacturing site in Wuxi, Jiangsu Province, China.

    Source:

  • Sep 23, 2026, 16:01 UTC

    The European Union approved AstraZeneca's Trixeo for the treatment of asthma, adding an indication supported by phase III data showing improved lung function.

    Source:

  • Sep 23, 2026, 12:10 UTC

    Polaris Rx was selected as the exclusive U.S. distributor of AstraZeneca's FluMist Home at-home flu vaccine service for the 2026-2027 flu season, the second consecutive year it has held the role.

    Source:

  • Sep 23, 2026, 08:14 UTC

    AstraZeneca announced a new five-year phase of its Young Health Programme with UNICEF and 60 NGOs, aiming to reach 10 million more young people and train 800,000 youth advocates by 2030 with cumulative investment expected to exceed $100 million.

  • Sep 23, 2026, 07:57 UTC

    The European Commission approved AstraZeneca's Trixeo Aerosphere for maintenance treatment of asthma in patients aged 12 and older whose condition is not adequately controlled by dual inhaled therapy.

    Source:

  • Sep 22, 2026, 21:59 UTC

    An Integrated Genomic Sequencing Centre was inaugurated at the NATCO Cancer Centre at Government General Hospital in Guntur, established in collaboration with AstraZeneca and Strand Life Sciences.

    Source:

  • Sep 21, 2026, 18:31 UTC

    The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for AstraZeneca's Klygefa for the treatment of AChR-positive generalised myasthenia gravis in the EU.

    Source:

  • Sep 18, 2026, 18:00 UTC

    The FDA granted priority review to AstraZeneca's filing for efzimfotase alfa, a treatment for the rare bone disease hypophosphatasia (HPP).

    Source:

  • Sep 18, 2026, 10:02 UTC

    AstraZeneca CEO Soriot bought ordinary shares of the company worth £7.26 million.

    Source:

  • Sep 17, 2026, 13:30 UTC

    The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.

    Source:

  • Sep 17, 2026, 07:15 UTC

    Bavarian Nordic A/S appointed Tarja Stenvall as President and Chief Executive Officer effective October 15, 2026, succeeding Paul Chaplin.

    Source:

  • Sep 17, 2026, 03:26 UTC

    AstraZeneca announced an investment of nearly RMB 200 million to upgrade the new drug development and supply building at its Wuxi production and supply base for process development and production of an investigational cardiovascular drug and global supply after commercialization.

    Source:

  • Sep 15, 2026, 11:34 UTC

    AstraZeneca's Japan subsidiary invited three Japanese drug-discovery and medical-device startups, including Cuorips, to its global headquarters in Cambridge, UK, for discussions on overseas expansion as part of an Osaka Prefecture-backed startup support program.

    Source:
← PreviousPage 2Next →